Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 1401 - 1425 of 2320 in total
PR006 is a non-replicating recombinant adeno-associated virus serotype 9 containing the progranulin gene. It is being investigated for the treatment of dementia.
Investigational
Matched Description: … PR006 is a non-replicating recombinant adeno-associated virus serotype 9 containing the progranulin gene …
ACTX-401 is a single-stranded, non-replicating recombinant adeno-associated viral vector serotype 9 containing the human immunoglobulin u-binding protein 2 cDNA.
Investigational
Matched Description: … ACTX-401 is a single-stranded, non-replicating recombinant adeno-associated viral vector serotype 9 containing …
ATA-100 is an adeno-associated virus serotype 9 carrying the human Fukutin-Related protein gene and target sequence of the miR-208a
Investigational
Matched Description: … ATA-100 is an adeno-associated virus serotype 9 carrying the human Fukutin-Related protein gene and target …
GS-100 is an adeno-associated virus serotype 9 virus particle containing viral DNA that includes an expression cassette containing the human NGLY1 gene coding sequence
Investigational
Matched Description: … GS-100 is an adeno-associated virus serotype 9 virus particle containing viral DNA that includes an expression …
Plumbagin is a compound investigated for its anticancer activity. It has been found that it inactivates the Akt/NF-kB, MMP-9 and VEGF pathways.
Investigational
Matched Description: … It has been found that it inactivates the Akt/NF-kB, MMP-9 and VEGF pathways.[A253102] …
BMS-986020 is under investigation in clinical trial NCT02017730 (To Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding in Lung Using PET (Positron Emission Tomography) In Healthy Volunteers).
Investigational
JLK-247 is an adeno-associated viral vector serotype 9 (AAV9)-mediated gene replacement therapy for the treatment of Sanfilippo Syndrome Type C or MPS IIIC.
Investigational
Matched Description: … JLK-247 is an adeno-associated viral vector serotype 9 (AAV9)-mediated gene replacement therapy for the …
The use of the plant species Cannabis sativa and Cannabis indica, popularly known as marijuana, has gained popularity in recent years for the management of a wide variety of medical conditions as a wave of legalization in North America has changed public and medical opinion on its use. Consequently, an...
Experimental
Investigational
Matched Description: … The primary psychoactive component of Cannabis, delta 9-tetrahydrocannabinol (Δ9-THC), demonstrates its …
The principal cyclooxygenase metabolite of arachidonic acid. It is released upon activation of mast cells and is also synthesized by alveolar macrophages. Among its many biological actions, the most important are its bronchoconstrictor, platelet-activating-factor-inhibitory, and cytotoxic effects.
Investigational
Fenproporex is an orally active stimulant drug, which was developed in the 1960s. It is used as an appetite suppressant and a treatment for obesity. It is listed as an illicit substance in many countries due to addiction issues and listed as a prohibited substance by the World Anti-Doping Agency....
Experimental
Illicit
Withdrawn
MK-8777 is under investigation in clinical trial NCT00610649 (Trial to Determine the Maximum Tolerated Dose (MTD) Based on Safety and Tolerability, of Org 26576 in Participants With Major Depressive Disorder (174001/P05704/MK-8777-001)).
Investigational
Ketobemidone is a powerful opioid analgesic. It also has some NMDA-antagonist properties. This makes it useful for some types of pain that don't respond well to other opioids. The most commonly cited equalisation ratio for analgesic doses is 25 mg of ketobemidone hydrobromide to 60 mg of morphine hydrochloride or...
Investigational
Matched Description: … most commonly cited equalisation ratio for analgesic doses is 25 mg of ketobemidone hydrobromide to 60
Experimental
CIGB-258 is a peptide that is immunoregulatory and derived from heat shock protein 60 of the cellular variant. As of 2020, The Center for Genetic Engineering and Biotechnology (CIGB) in Havana, Cuba, is testing the treatment efficacy of this peptide in patients with COVID-19 who are under intensive therapy regimens...
Investigational
Matched Description: … CIGB-258 is a peptide that is immunoregulatory and derived from heat shock protein 60 of the cellular …
SBT101 is a non-replicating recombinant adeno-associated virus serotype 9 (AAV9) gene therapy vector containing the human adenosine triphosphate (ATP)-binding cassette (ABC) sub-family D member 1 (ABCD1) gene.
Investigational
Matched Description: … SBT101 is a non-replicating recombinant adeno-associated virus serotype 9 (AAV9) gene therapy vector …
Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Icotinib was approved in China by the SFDA in June, 2011 and in January 2014, Beta Pharma, Inc. was given a “May Proceed” from the US FDA to conduct a Phase I study for the...
Experimental
Investigational
CPG 10101 is a synthetic oligodeoxynucleotide (ODN) in clinical trials. It is a toll-like receptor 9 (TLR9) agonist with antiviral and immunomodulatory properties that could potentially influence chronic infection with HCV.
Investigational
Matched Description: … It is a toll-like receptor 9 (TLR9) agonist with antiviral and immunomodulatory properties that could …
Technetium-99m is the metastable isotope of technetium. It is commonly symbolized as 99mTc and used in the area of medical diagnosis. Technetium-99m is the most commonly used medical radioisotope.
Experimental
MK-4541 is a 4-azasteroid and a selective androgen receptor modulator (SARM). MK-4541 acts as a dual selective SARM and is both a potent androgen receptor antagonist and a 5α-reductase inhibitor.
Investigational
TAFA93 is a novel prodrug of the mTOR inhibitor rapamycin which has successfully completed Phase 1 clinical development. mTOR inhibitors are currently used in the prevention of organ rejection in transplantation, the treatment of autoimmune and oncological diseases, and as a component of coated stents for the treatment of coronary...
Investigational
OSI-930 is an orally active inhibitor of two clinically validated targets: c-Kit and the vascular endothelial growth factor receptor-2 (VEGFR-2). OSI-930 is designed to target both cancer cell proliferation and blood vessel growth (angiogenesis) in selected tumors. In preclinical studies, OSI-930 shows broad efficacy in tumor models representative of small...
Investigational
R-95845 is an inhibitor of HIV-1 reverse transcriptase.
Experimental
TAK-901 has been used in trials studying the treatment of Lymphoma, Myelofibrosis, Multiple Myeloma, Myeloid Metaplasia, and Advanced Solid Tumors, among others.
Investigational
Displaying drugs 1401 - 1425 of 2320 in total